Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

NCT02356458 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

58

Enrollment

OTHER

Sponsor class

Stopped SAKK Board decision of 14th November 2020 due to financial reasons.

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: bortezomib

Sponsor

Swiss Cancer Institute

Collaborators

[object Object]